Recist and beyond

JBR-BTR

Volumn 96, Issue 3, 2013, Pages 167-171

  Coche, E ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

CT; Lung neoplasms

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; HUMAN; IMAGE PROCESSING; MULTIDETECTOR COMPUTED TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SOLID TUMOR; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

EID: 84881493807     PISSN: 17802393     EISSN: None     Source Type: Journal    
DOI: 10.5334/jbr-btr.242     Document Type: Article

References (14)

1. World Health Organization. Who Handbook for Reporting Results of Cancer Treatment. Offset Publication, Geneva, Switzerland, 1979.
2. Park J.O., Lee S.I., Song S.Y., et al.: Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol, 2003, 33: 533-537.
3. Therasse P., Arbuck S.G., Eisenhauer E.A., et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst, 2000, 92: 205-216.
4. Eisenhauer E.A., Therasse P., Bogaerts J., et al.: New response evaluation criteria in solid tumors: revised RECIST guidelines (version 1.1). Eur J Cancer, 2009, 45: 228- 247.
5. Spears C.P.: Volume doubling measurement of spherical and ellipsoïdaltumors. Med Pediatr Oncol, 1984, 12: 212-217.
6. Oxnard G.R., Zhao B., Sima C., et al.: Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol, 2011, 29: 3114-3119.
7. Zeman R.X., Fox S.H., Silverman P.M., et al.: Helical (spiral) CT of the abdomen. Am J Roentgenol, 1993, 160: 719-725.
8. Hopper K.D., Kasales C.J., Eggli K.D., et al.: The impact of 2D versus 3D quantification of tumor bulk determination on current methods of assessing response to treatment. J Comput Assist Tomogr, 1996, 20: 930-937.
9. Mozley P.D., Bendtsen C., Zhao B., et al.: Measurement of tumor volumes improves RECIST-based response assessment in Advanced lung cancer. Translational Oncology, 2012, 5: 19- 25.
10. Choi H.: Critical issues in response evaluation on computed tomography: lessons from gastrointestinal stromal tumor model. Curr Oncol Rep, 2005, 7: 307-311.
11. De Leyn P., Stroobants S., De Wever W., et al.: Prospective comparative study of integrated positron emission tomography-computed tomography scan compared compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol, 2006, 24: 3333-3339.
12. Eschmann S.M., Friedel G., Paulsen F., et al.: Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 2007, 55: 165-171.
13. Sunaga N., Oriuchi K., Kaira K., et al.: Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer, 2008, 59: 203-210.
14. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A.: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med, 2009, 50: 122S-150S.